Graham Capital Management’s Akero Therapeutics AKRO Stock Holding History

Graham Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,752	Closed	-$795K	–	1204
2025 Q3	$795K	Sell	16,752 -1,551	-8%	-$75.1K	0.01%	453
2025 Q2	$977K	Buy	+18,303	New	+$832K	0.01%	588
2024 Q4	–	Sell	-13,396	Closed	-$384K	–	1210
2024 Q3	$384K	Buy	13,396 +2,499	+23%	+$65.2K	0.01%	712
2024 Q2	$256K	Buy	+10,897	New	+$233K	0.01%	776

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Graham Capital Management's AKRO Position: Q4 2025 in Review

Graham Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 16,752 shares — an estimated $795K sold.

Graham Capital Management first reported a position in AKRO in Q2 2024 and held it in 4 quarters. The position peaked at $977K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Graham Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Graham Capital Management sold 16,752 Akero Therapeutics shares in Q4 2025, an estimated $795K.
Graham Capital Management first reported a position in Akero Therapeutics in Q2 2024 and held it in 4 quarters.
Graham Capital Management's Akero Therapeutics position peaked at $977K in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.